Circulating Th17, Th22, and Th1 Cells Are Elevated in the Guillain-Barré Syndrome and Downregulated by IVIg Treatments

Figure 5

IVIg treatments downregulate CD4⁺IFN-𝛾⁺, CD4⁺IL-22⁺, and Th1, Th1/Th17, Th17, and Th22 cells and their cytokines at the plateau phase of GBS. A total of 24 GBS patients were treated with IVIg, and Th1, Th17, and Th22 cells as well as plasma levels of IL-17 and IL-22 were determined before (black bar) and after treatment (white bar). (a) Bar plot of the percentages of CD4⁺IFN-𝛾⁺, Th17 (CD4⁺IL-17A⁺), and CD4⁺IL-22⁺ cells on the gated lymphocytes in the FSC/SSC plot. (b) Bar plot of the percentages of Th1 (IFN-𝛾⁺IL-17A⁻IL-22⁻), Th1/Th17 (IFN-𝛾⁺IL-17A⁺IL-22⁻), Th17 (IFN-𝛾⁻IL-17A⁺IL-22⁻, IFN-𝛾⁻IL-17A⁺IL-22⁺), and Th22 (IFN-𝛾⁻IL-17A⁻IL-22⁺) cells on CD4⁺ cells. (c) Bar plot of the levels of plasma of IL-17 and IL-22. Results are represented as the mean ± SD. Statistical significance was indicated: ^∗𝑃<0.05, ^∗∗𝑃<0.01, and ^∗∗∗𝑃<0.001.

(a)

(b)

(c)